Specific genetic variants of LGALS3 influence the risk of developing TC, and its role in the invasiveness of BRAF-mutated papillary thyroid carcinoma highlights its potential as a therapeutic target in tumor progression [42, 43]. Here, LGALS3 is linked to differentiated thyroid carcinoma.